netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:
Please also refer to the Cancer Drugs Fund list
 Details...
08.01  Expand sub section  Cytotoxic drugs
 note  Cytotoxic chemotherapy for malignant disease should only be prescribed by a specialist registrar or consultant with adequate experience in this area
08.01  Expand sub section  Side-effects of cytotoxic drugs
Amifostine injection

Restricted Drug Unlicensed
Red
Prevention of cumulative renal toxicity associated with repeated administration of cisplatin
   
08.01  Expand sub section  Drugs for cytotoxic-induced side-effects
08.01.01  Expand sub section  Alkylating drugs
 note  Use in accordance with local guidelines
08.01.02  Expand sub section  Anthracyclines and other cytotoxic antibiotics to top
 note  Use in accordance with local guidelines
08.01.03  Expand sub section  Antimetabolites
 note  Use in accordance with local guidelines
08.01.04  Expand sub section  Vinca alkaloids and etoposide
 note  Use in accordance with local guidelines
08.01.05  Expand sub section  Other antineoplastic drugs
 note  Use in accordance with local guidelines
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Bevacizumab to top
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors
08.01.05  Expand sub section  Taxanes to top
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab
08.01.05  Expand sub section  Tretinoin
 ....
Key
note Notes First Choice Item First Choice item
Section Title Section Title (top level) Non Formulary Item Non Formulary section
Section Title Section Title (sub level)
Cytotoxic Drug
Cytotoxic Drug
Restricted Drug
Restricted Drug
CD
Controlled Drug
Unlicensed Drug
Unlicensed
High Cost Medicine
High Cost Medicine
click to search medicines.org.uk
Link to SPCs
click to search medicines.org.uk
Link to adult BNF
Track Changes
Display tracking information
click to search medicines.org.uk
Cancer Drugs Fund
Cancer Drugs Fund
   

 

Traffic Light Status Information

Status Description
  Red   Specialist Prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   
  Amber 1   Treatment can be initiated in primary care after a recommendation from an appropriate specialist  
  Amber 2   Specialist initiation followed by maintenance prescribing in primary care  
  Amber 3   Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  
  Green   Specialist and non-specialist initiation  
  Grey   Not recommended for prescribing  

netFormulary